AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19825207 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g dark chocolate with 1000 mg polyphenols
Number of subjects: 14
Study 19825207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of dark chocolate
Number of subjects: 14
Study 19825207 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 14
Study 17885595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal words presented with long interstimulus intervals
Number of subjects: 0
Study 17885595 — intervention group
Group type: EXPERIMENTAL
Intervention: Single presentation of a masked word
Number of subjects: 0
Study 16083519 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan ODT
Number of subjects: 186
Study 11879129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 419
Study 11879129 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 419
Study 9689420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release tablet (40 mg)
Number of subjects: 10
Study 9689420 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (20 mg)
Number of subjects: 10
Study 7857348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg ampoule twice a day)
Number of subjects: 50
Study 7857348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7857348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 50
Study 2776821 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil-SR 360 mg once daily
Number of subjects: 10
Study 2776821 — intervention group
Group type: COMPARATOR
Intervention: verapamil-IR 120 mg t.i.d.
Number of subjects: 10
Study 2776821 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil-SR 240 mg
Number of subjects: 10
Study 2776821 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil-SR
Number of subjects: 10
Study 2776821 — intervention group
Group type: COMPARATOR
Intervention: verapamil-IR
Number of subjects: 10
Study 1110438 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra contact with infants during the neonatal period
Number of subjects: 10
Study 1110438 — intervention group
Group type: COMPARATOR
Intervention: Control group (less contact with infants)
Number of subjects: 10
Study 31032913 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Migraine (CM)
Number of subjects: 516
Study 29143926 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer plus body wash (twice daily moisturizer and once daily body wash)
Number of subjects: 64
Study 29143926 — intervention group
Group type: COMPARATOR
Intervention: Body wash alone (once daily)
Number of subjects: 64
Study 29143926 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer plus body wash
Number of subjects: 64
Study 29143926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 64
Study 25664642 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback only intervention (PFB)
Number of subjects: 333
Study 25664642 — intervention group
Group type: COMPARATOR
Intervention: Education only (EDU)
Number of subjects: 333
Study 25664642 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 333
Study 23349102 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich bilberry pomace extract (BE)
Number of subjects: 0
Study 22048089 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with acromioplasty
Number of subjects: 68
Study 22048089 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without acromioplasty
Number of subjects: 68
Study 19371267 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg day(-1))
Number of subjects: 44
Study 19371267 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg day(-1))
Number of subjects: 44
Study 17029278 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX type A (BTX‐A) plus a specific program of physical therapy (BTX‐PT)
Number of subjects: 40
Study 17029278 — intervention group
Group type: COMPARATOR
Intervention: BTX type A (BTX‐A) alone (BTX‐0)
Number of subjects: 40
Study 15028348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 428
Study 15028348 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 428
Study 11394701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrate citrate lock
Number of subjects: 19
Study 11394701 — intervention group
Group type: COMPARATOR
Intervention: Heparin lock
Number of subjects: 19
Study 9119756 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral broad-band noise at 60 dB SPL RMS
Number of subjects: 4
Study 9119756 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral broad-band noise
Number of subjects: 4
Study 8098788 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln TPN (parenteral nutrition enriched with glycyl‐L‐glutamine)
Number of subjects: 20
Study 8098788 — intervention group
Group type: COMPARATOR
Intervention: STPN (standard parenteral nutrition)
Number of subjects: 20
Study 3548350 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin (0.5, 1.0, or 1.5 g weekly for up to six months)
Number of subjects: 41
Study 29480316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g oat β-glucan (OBG)
Number of subjects: 40
Study 29480316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g oat β-glucan (OBG)
Number of subjects: 40
Study 29480316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g oat β-glucan (OBG)
Number of subjects: 40
Study 29480316 — intervention group
Group type: COMPARATOR
Intervention: Instant oatmeal plus 247 g 2% milk (IO)
Number of subjects: 40
Study 29480316 — intervention group
Group type: COMPARATOR
Intervention: Cream of rice (CR) plus milk
Number of subjects: 40
Study 27595528 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin/day for 2 days preoperatively
Number of subjects: 94
Study 27595528 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of atorvastatin/day for 5‐9 days preoperatively
Number of subjects: 94
Study 27595528 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin/day for 5‐9 days preoperatively
Number of subjects: 94
Study 27595528 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 94
Study 25029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 32
Study 25029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham OMT
Number of subjects: 32
Study 25029347 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study 25029347 — intervention group
Group type: COMPARATOR
Intervention: Cervical pain, headache, and quality of life (QOL)
Number of subjects: 32
Study 22057385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating platform mobile bearing TKA (Group A, n = 40)
Number of subjects: 80
Study 22057385 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing TKA (Group B, n = 40)
Number of subjects: 80
Study 22057385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating platform mobile bearing TKA (Group A)
Number of subjects: 80
Study 22057385 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing TKA (Group B)
Number of subjects: 80
Study 22057385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 20519098 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg/d)
Number of subjects: 34
Study 20519098 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (5 mg/d)
Number of subjects: 34
Study 18786264 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 14394
Study 18786264 — intervention group
Group type: COMPARATOR
Intervention: Good vision (Control)
Number of subjects: 14394
Study 18786264 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment (adjusted for a wide range of potential explanatory factors)
Number of subjects: 14394
Study 18786264 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment (adjusted for a limited range of confounding factors)
Number of subjects: 14394
Study 15721112 — intervention group
Group type: COMPARATOR
Intervention: FilterWire EX
Number of subjects: 572
Study 15721112 — intervention group
Group type: COMPARATOR
Intervention: GuardWire
Number of subjects: 572
Study 12872610 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5/13
Number of subjects: 20
Study 12872610 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 70/0.5/4
Number of subjects: 20
Study 12872610 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5/13 and HES 70/0.5/4
Number of subjects: 20
Study 10597203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analysis by experts
Number of subjects: 0
Study 10597203 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized CT staging by experienced investigators
Number of subjects: 0
Study 10597203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biological risk factor analysis and CT staging
Number of subjects: 0
Study 10597203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analysis and/or CT staging in non-specialized centers
Number of subjects: 0
Study 7489937 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily
Number of subjects: 2435
Study 7489937 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1200 mg daily
Number of subjects: 2435
Study 7489937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2435
Study 1792400 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 20
Study 1792400 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 5 mg/kg
Number of subjects: 20
Study 1792400 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 20
Study 6113479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff blood pressure measurements
Number of subjects: 59
Study 6113479 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 59
Study 30883334 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 70
Study 30883334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 70
Study 30883334 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 28544128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with radiation therapy followed by adjuvant cetuximab and irinotecan (5,940 cGy radiation, cetuximab weekly, irinotecan daily for 5 days per week for 2 weeks every 21 days for 30 weeks)
Number of subjects: 45
Study 28544128 — intervention group
Group type: COMPARATOR
Intervention: Historical controls for overall survival comparison
Number of subjects: 45
Study 25869284 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing of pomalidomide/dexamethasone
Number of subjects: 0
Study 25869284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of pomalidomide/dexamethasone
Number of subjects: 0
Study 25869284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Number of subjects: 0
Study 25869284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing regimens (continuous and intermittent)
Number of subjects: 0
Study 23677919 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir intensification
Number of subjects: 44
Study 23677919 — intervention group
Group type: COMPARATOR
Intervention: Control (same regimen)
Number of subjects: 44
Study 23677919 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intensification arm (after 24 weeks of control)
Number of subjects: 44
Study 23677919 — intervention group
Group type: COMPARATOR
Intervention: Both arms (Raltegravir and Control)
Number of subjects: 44
Study 23677919 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in CD4 T cell counts
Number of subjects: 44
Study 22773702 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 240
Study 22773702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 20025778 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (intranasal)
Number of subjects: 0
Study 20025778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17488782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 33
Study 17488782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 33
Study 17488782 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral misoprostol (800 microg)
Number of subjects: 33
Study 17488782 — intervention group
Group type: COMPARATOR
Intervention: Conventional misoprostol (vaginal or sublingual)
Number of subjects: 33
Study 15130977 — intervention group
Group type: EXPERIMENTAL
Intervention: Training care givers in basic nursing and facilitation of personal care techniques
Number of subjects: 300
Study 11239194 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral carotid endarterectomy (CEA)
Number of subjects: 19
Study 9549794 — intervention group
Group type: COMPARATOR
Intervention: Functional restoration program (Project A)
Number of subjects: 238
Study 9549794 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration program (Project B)
Number of subjects: 238
Study 7944416 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 administered preoperatively via hepatic artery
Number of subjects: 10
Study 7944416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with OK-432)
Number of subjects: 10
Study 3284269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg thiopentone
Number of subjects: 33
Study 3284269 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg thiopentone
Number of subjects: 33
Study 3284269 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 33
Study 2177499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline capsules (administered daily for 2 weeks)
Number of subjects: 0
Study 2177499 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (administered daily for 2 weeks)
Number of subjects: 0
Study 2177499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline capsules (in vitro exposure)
Number of subjects: 0
Study 2177499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline capsules (in additional subjects)
Number of subjects: 0
Study 9583 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 31471729 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 1379
Study 31471729 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1379
Study 27711048 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7713 (20 mg intravenous dose)
Number of subjects: 19
Study 25198284 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus standard prize CM (average expected prize earnings about $300)
Number of subjects: 240
Study 25198284 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus high magnitude prize CM (average expected prize earnings about $900)
Number of subjects: 240
Study 25198284 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus voucher CM (expected maximum of about $900 in vouchers)
Number of subjects: 240
Study 25198284 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 240
Study 25198284 — intervention group
Group type: EXPERIMENTAL
Intervention: All CM conditions
Number of subjects: 240
Study 25198284 — intervention group
Group type: EXPERIMENTAL
Intervention: CM conditions
Number of subjects: 240
Study 23274594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated hot (HYH)
Number of subjects: 12
Study 23274594 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 12
Study 21029512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (n=7)
Number of subjects: 15
Study 21029512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 15
Study 19841457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tidal volume (Vt) ventilation
Number of subjects: 3596
Study 19841457 — intervention group
Group type: COMPARATOR
Intervention: Higher PEEP
Number of subjects: 3596
Study 16797484 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive style of rumination
Number of subjects: 80
Study 16797484 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 80
Study 16797484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 80
Study 16797484 — intervention group
Group type: COMPARATOR
Intervention: No training control
Number of subjects: 80
Study 15539964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg monotherapy
Number of subjects: 0
Study 15539964 — intervention group
Group type: COMPARATOR
Intervention: ER niacin 2 g monotherapy
Number of subjects: 0
Study 15539964 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg plus ER niacin 2 g
Number of subjects: 0
Study 15539964 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg plus ER niacin 0.5-2 g
Number of subjects: 0
Study 15539964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin monotherapy
Number of subjects: 0
Study 11686658 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography-guided strategy with short-term anticoagulation
Number of subjects: 0
Study 11686658 — intervention group
Group type: COMPARATOR
Intervention: Conventional long-term anticoagulation
Number of subjects: 0
Study 9017550 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 16000
Study 9017550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study 7953902 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused and neglected individuals
Number of subjects: 699
Study 7953902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 699
Study 3309752 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate (single dose)
Number of subjects: 18
Study 3309752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study 31925771 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal obesity (BMI > 30 kg/m2)
Number of subjects: 484
Study 31925771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal sex (male)
Number of subjects: 484
Study 31925771 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI progression
Number of subjects: 484
Study 31925771 — intervention group
Group type: COMPARATOR
Intervention: Fetal sex and maternal BMI
Number of subjects: 484
Study 30321315 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 42
Study 30321315 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 27717113 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months healing time before implant placement
Number of subjects: 66
Study 27717113 — intervention group
Group type: COMPARATOR
Intervention: 6 months healing time before implant placement
Number of subjects: 66
Study 25560227 — intervention group
Group type: EXPERIMENTAL
Intervention: 6× weekly in-center hemodialysis (frequent HD)
Number of subjects: 332
Study 25560227 — intervention group
Group type: EXPERIMENTAL
Intervention: 6× weekly nocturnal hemodialysis (frequent HD)
Number of subjects: 332
Study 25560227 — intervention group
Group type: COMPARATOR
Intervention: 3× weekly hemodialysis (conventional HD)
Number of subjects: 332
Study 23497486 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention for GPs including an online active learning module, moderated discussion forum, targeted specialist advice, and town-based performance feedback.
Number of subjects: 22
Study 23497486 — intervention group
Group type: COMPARATOR
Intervention: Control group (towns not receiving the intervention).
Number of subjects: 22
Study 21706221 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Divalproex sodium (up to 1,500 mg/day)
Number of subjects: 58
Study 21706221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Divalproex sodium (up to 250 mg/day)
Number of subjects: 58
Study 21706221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 18448393 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention alone
Number of subjects: 0
Study 18448393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of primary and secondary prevention
Number of subjects: 0
Study 18448393 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 0
Study 16541843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pró‐Fono Facial Exerciser
Number of subjects: 39
Study 16541843 — intervention group
Group type: COMPARATOR
Intervention: Control group (bruxers without device)
Number of subjects: 39
Study 16541843 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 39
Study 16541843 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bruxer group (using device)
Number of subjects: 39
Study 14550900 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine (2.5 mg) with naloxone (0.2 mg)
Number of subjects: 0
Study 14550900 — intervention group
Group type: COMPARATOR
Intervention: nalbuphine (2.5 mg)
Number of subjects: 0
Study 14550900 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine (5 mg) with naloxone (0.4 mg)
Number of subjects: 0
Study 14550900 — intervention group
Group type: COMPARATOR
Intervention: nalbuphine (2.5 mg) with naloxone (0.4 mg)
Number of subjects: 0
Study 10227933 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Nissen‐Rossetti fundoplication (n = 53)
Number of subjects: 106
Study 10227933 — intervention group
Group type: COMPARATOR
Intervention: Toupet partial posterior fundoplication (n = 53)
Number of subjects: 106
Study 8693548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine microemulsion (mean dose: 5.9 mg/kg/day, range: 3.0‐11.7 mg/kg/day)
Number of subjects: 22
Study 8693548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine microemulsion
Number of subjects: 22